SCYNEXIS To Participate In The 3Rd Annual Guggenheim Healthcare Innovation Conference
One-on-One Meetings
Dates: November 9-10, 2026
Fireside Chat
Date: Monday, November 9, 2026
Time: 2:30 p.m.-3:00 p.m. ET
A live webcast of the Guggenheim fireside chat will be available here. A replay of the webcast will be available on our website for 90 days following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS's proprietary antifungal platform“fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit .
CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment